Outpatient Oncology Infusion Market

• The global outpatient oncology infusion market is valued at USD 8.90 Billion in 2026 and is projected to reach USD 16.37 Billion by 2033, expanding at a CAGR of 9.1% across the 2026-2033 forecast period.
• Infusion Services lead the segment with a 46.0% share in 2026, equivalent to USD 4.09 Billion.
• Physician Office-Based Infusion Centers remain the dominant care setting, accounting for 42.0% of global demand, or USD 3.74 Billion, in 2026.
• North America commands the largest regional share at 47.0% of the global market in 2026.
• Freestanding ambulatory infusion centers are emerging as the fastest-growing care setting through 2033.

Outpatient oncology infusion encompasses the equipment, consumables, and clinical services required to deliver chemotherapy, immunotherapy, and supportive care infusions to cancer patients outside of inpatient hospital settings. As cancer treatment protocols increasingly favor outpatient delivery to reduce cost and improve patient quality of life, this market spans infusion pumps and devices, disposable consumables and supplies, and the clinical infusion services delivered across hospital-affiliated, physician office-based, and freestanding ambulatory infusion centers.

Demand growth through the 2026-2033 window is closely tied to rising global cancer incidence and the corresponding growth in infusion-based treatment volumes, sustained policy and payer preference for shifting cancer care from inpatient to lower-cost outpatient settings, and expanding availability of newer infusion-based immunotherapy and targeted therapy regimens that have broadened the range of cancers treated through infusion protocols. Growing investment in freestanding ambulatory infusion center infrastructure is also reshaping where this care is delivered.

The market is valued at USD 8.90 Billion in 2026, with providers and equipment manufacturers directing investment toward infusion center capacity expansion and improved infusion technology supporting safer, more efficient outpatient chemotherapy delivery. By 2033, the market is forecast to reach USD 16.37 Billion, reflecting accelerating growth as outpatient infusion delivery continues to expand relative to inpatient alternatives.

Growth in the outpatient oncology infusion market is driven primarily by rising global cancer incidence, which is increasing the overall population of patients requiring infusion-based treatment across an expanding range of cancer types as diagnostic detection and treatment protocols continue to advance.

A second driver is sustained payer and health system preference for outpatient care delivery, as outpatient oncology infusion typically costs meaningfully less than equivalent inpatient hospital-based treatment while offering comparable clinical outcomes and improved patient convenience, creating consistent policy and reimbursement support for continued outpatient care migration.

Reimbursement complexity and variability across different payer types and care settings creates administrative burden for infusion providers, since payment rates and coverage policies for the same infusion service can differ substantially between hospital-affiliated, physician office-based, and freestanding infusion center settings, complicating financial planning for providers operating across multiple settings.

Additionally, the clinical complexity of managing infusion-related adverse events in outpatient settings, without the immediate escalation resources available in a hospital environment, requires robust clinical protocols and staffing that add operational cost and complexity relative to simpler outpatient infusion applications.

The continued expansion of freestanding ambulatory infusion centers presents a substantial opportunity, as these lower-overhead care settings can often deliver infusion services more cost-effectively than hospital-affiliated alternatives while offering patients a more convenient, less clinical treatment environment.

A second opportunity lies in the growing range of infusion-based immunotherapy and targeted therapy regimens entering clinical use, as these newer treatment modalities are expanding the population of cancer patients eligible for infusion-based treatment beyond the traditional chemotherapy patient base, broadening the market's overall addressable patient population.

By Type

Infusion Services lead the segment, accounting for 46.0% of global market value in 2026, equivalent to USD 4.09 Billion. Their leadership reflects the clinical staffing, monitoring, and care coordination that represents the largest cost component of outpatient infusion delivery. Infusion Consumables & Supplies hold a significant secondary share tied directly to treatment volume. Infusion Pumps & Devices represent a smaller but steadily growing category as ambulatory and portable pump technology continues to advance.

By Care Setting

Physician Office-Based Infusion Centers form the leading care setting, representing 42.0% of global demand in 2026, or USD 3.74 Billion, reflecting their established role in oncology practice-based care delivery. Hospital-Affiliated Outpatient Infusion Centers represent a significant, established care setting. Freestanding Ambulatory Infusion Centers represent the fastest-growing care setting category, propelled by their cost efficiency and growing investment in dedicated infusion center infrastructure.

North America

North America holds the largest regional share, at 47.0% of the global market in 2026, equivalent to USD 4.18 Billion. The region's leadership reflects its well-established outpatient oncology care infrastructure, strong payer support for outpatient care migration, and substantial investment in ambulatory infusion center development across the United States and Canada.

Europe

Europe accounts for 25.0% of the global market in 2026, valued at USD 2.23 Billion. Demand is supported by the region's coordinated healthcare systems increasingly favoring outpatient cancer care delivery to manage healthcare costs while maintaining treatment quality.

Asia Pacific

Asia Pacific represents 20.0% of the global market in 2026, or USD 1.78 Billion. Growth is underpinned by rising cancer incidence and expanding oncology care infrastructure investment across China, Japan, and other regional markets.

Latin America

Latin America contributes 5.0% of the global market in 2026, equivalent to USD 0.45 Billion. Growth is linked to gradual oncology care infrastructure expansion in Brazil and Mexico as outpatient care models gain broader adoption.

Middle East & Africa

Middle East & Africa holds 3.0% of the global market in 2026, valued at USD 0.27 Billion. Growth remains gradual, tied to oncology care infrastructure development across the region, with concentration in more developed Gulf Cooperation Council healthcare markets.

The global outpatient oncology infusion market is moderately fragmented, with a mix of large oncology practice networks and infusion service providers operating across multiple care settings, alongside established medical device manufacturers supplying infusion pumps and consumables used throughout the treatment pathway. Competition centers on clinical care quality, infusion center accessibility and convenience, and the ability to navigate complex payer reimbursement arrangements across different care settings. Providers are increasingly differentiating through expanded ambulatory infusion center networks rather than competing on hospital-based service delivery alone.

Key Market Players

• Option Care Health, Inc.
• Baxter International Inc.
• ICU Medical, Inc.
• B. Braun Melsungen AG
• Fresenius Kabi AG
• Becton, Dickinson and Company
• US Oncology, Inc.
• American Oncology Network, LLC
• Cardinal Health, Inc.
• Ivenix, Inc.

By Type

• Infusion Services
• Infusion Consumables & Supplies
• Infusion Pumps & Devices

By Care Setting

• Physician Office-Based Infusion Centers
• Hospital-Affiliated Outpatient Infusion Centers
• Freestanding Ambulatory Infusion Centers

By Cancer Type

• Solid Tumors
• Hematologic Malignancies

By Geography

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa